Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
mAbs journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Nathalie Kersual, Véronique Garambois, Thierry Chardès, Jean-Pierre Pouget, Imed Salhi, Caroline Bascoul-Mollevi, Frédéric Bibeau, Muriel Busson, Henri Vié, Béatrice Clémenceau, Christian K Behrens, Pauline Estupina, André Pèlegrin & Isabelle Navarro-Teulon (2014) The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, mAbs, 6:5, 1314-1326
Two studies on AMHR2 project were accepted for a publication in mAbs journal and a poster by Institut Curie (Paris, France) at the 10th Biennial Ovarian Cancer Research Symposium (Seattle, 8-9 September 2014)
Start-up magazine publishes an article on GamaMabs Pharma in its April 2014 issue dedicated to antibodies.
Alto Invest joins GamaMabs investors with a €0.5m equity financing and Bpifrance awards a €0.6m reimbursable aid for the development of 3C23K program in ovarian cancer.